FSA
VTGN icon

Fort Sheridan Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Fort Sheridan Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-500
Closed -$11K – 115
2019
Q2 		$11K Hold
500
– – 0.01% 103
2019
Q1 		$19K Hold
500
– – 0.01% 99
2018
Q4 		$23K Buy
+500
New +$27.2K 0.02% 85

Other funds holding VTGN

William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Fort Sheridan Advisors's VTGN Position: Q3 2019 in Review

Fort Sheridan Advisors sold out of VistaGen Therapeutics (VTGN) in Q3 2019, closing a stake of 500 shares — an estimated $11K sold.

Fort Sheridan Advisors first reported a position in VTGN in Q4 2018 and held it in 3 quarters. The position peaked at $23K in Q4 2018. 24 funds tracked by Wall St. Rank hold VTGN as of Q3 2019.

  • Fort Sheridan Advisors reported no remaining VistaGen Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Fort Sheridan Advisors sold 500 VistaGen Therapeutics shares in Q3 2019, an estimated $11K.
  • Fort Sheridan Advisors first reported a position in VistaGen Therapeutics in Q4 2018 and held it in 3 quarters.
  • Fort Sheridan Advisors's VistaGen Therapeutics position peaked at $23K in Q4 2018.
  • 24 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2019.

Based on Fort Sheridan Advisors's 13F filing for Q3 2019, filed 12 Nov 2019.